Welcome to EQL Pharma's Investor Pages!

We strive to have an open and proactive dialogue with our shareholders.

54.00 SEK

To Stock Graph

0.00 (0.00%)

Spotlight Stock Market

Annual Report 2022/2023Read Here

Year End Report 2023/2024 (in Swedish)

Listen to CEO Axel Schörling present EQL Pharma's latest report (in Swedish)

Year End Report 2023/2024

Press Releases

2024-07-16

Notice of annual general meeting in EQL Pharma AB

Regulatory

The shareholders of EQL Pharma AB, Reg. No. 556713-3425, are hereby invited to the annual general meeting to be held on Monday 19 August 2024 at 16.00 at the company’s premises at Stortorget 1 in L...

2024-07-15

Invitation to presentation in connection with EQL Pharma's interim report, first quarter, 2024/25

EQL Pharma AB (publ) will publish its interim report for the first quarter, 2024/25, on Thursday, August 8[th], before stock markets opening.

2024-07-05

Mellozzan[® ](melatonin) has gained marketing approval in Switzerland

EQL's key product Mellozzan[®] has now gained marketing approval by the Health Authorities in Switzerland, where it is to be provided to patients by EQL's license partner Medice Arzneimittel Pütter...

Se all

EQL Pharma in Short

EQL Pharma is an entrepreneurial pharmaceutical company focusing on simplicity and efficiency at all levels of the value chain in order to be able to deliver cost-efficient medicines of highest quality to pharmacies and hospitals.